Search
Confirm
Close

ABOUT Viwit

With high-quality products and services, we continue to create more value for our customers, employees, shareholders and society, and contribute our talents and efforts to a healthier and better life

COMPANY PROFILE

    Viwit is an innovation driven biopharmaceutical and healthcare company with integrated research and development, production and marketing systems. Viwit is committed to building a platform for pharmaceutical innovation and commercialization, and establishing an ecosystem that serves the healthcare needs of the general public.

    Viwit was founded in 2006 as an R&D lab. With the collaborative efforts of the Viwit team, Viwit Pharmaceutical has evolved from developing chiral borane products to making drug intermediates, active pharmaceutical ingredients and biopharmaceutical products. Viwit has three integrated product research and development (R&D) centers, three cGMP production facilities (refer to history of Viwit), and marketing distribution systems in China, the United States, Canada, European Union and other regions. Viwit is continuously focusing and expanding its business scope and operations in the biopharmaceutical and healthcare industry.

PRODUCT INTRODUCTION

We are committed to developing into a global leading medical and health enterprise based on the overall competitive advantage of the industrial chain and based on technological innovation


HIGH DEMAND PRODUCTS

Adhering to customer demand, building core competitiveness, and striving to provide better and higher quality health products and services

Title

Levofloxacin Hydrochloride Injection 5ml: 0.5g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.5g<br/>
Title

Levofloxacin hydrochloride Injection 5ml: 0.3g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.3g<br/>
Title

Puerarin Injection 5ml: 0.25g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.25g<br/>
Title

Puerarin Injection 8ml: 0.4g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;8ml: 0.4g<br/>

INNOVATION 

& collaboration platform 

CDMO

Viwit platform provides CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, vials, eye drops). 

威智医药

Project Collaboration

Viwit platform provides R&D project cooperation and commercialization, covering the entire pharma industrial value chain from finished drugs to APIs.              

威智医药
威智医药

Joint Venture

Provide marketing, fund raising and other resources.

In-/Out-Licensing

Viwit is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets.

威智医药

NEWS CENTER

Make due contribution to the development of the industry and society, and strive to become the pacesetter and pioneer of the industry.

2024

07 -15

Recently, theViwit independently developed smoking cessation drug Varenicline (Tartrate) Tablets, in strengths of 0.5 mg and 1 mg, received the Drug Registration Certificate issued by the South African Health Products Regulatory Authority (SAHPRA).

2024

07 -12

On July 5, 2024, Viwit Pharmaceitical’s independently developed Fosaprepitant Dimeglumine API received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA). The registration number is Y20220000736, and the notice number is 2024YS00664.

2024

07 -09

Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Bimatoprost Eye Drops. The approval number is H20244103. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation, thereby becoming the second domestic generic drug of its kind.

2024

06 -17

Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for their Gadoterate Meglumine Injection. This approval includes the following strengths: 10 mL containing 3.769 g, 15 mL containing 5.654 g, and 20 mL containing 7.538 g. The corresponding approval numbers are H20243899, H20243900, and H20243901.

2024

06 -15

May 8, 2024 – Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for the drug product, Deslanoside Injection. The approval notice number is 2024B01980.